Estrone-Conjugated PEGylated Liposome Co-Loaded Paclitaxel and Carboplatin Improve Anti-Tumor Efficacy in Ovarian Cancer and Reduce Acute Toxicity of Chemo-Drugs

References

• Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3–14. doi:10.1016/j.bpobgyn.2016.08.006
   PubMed Web of Science ®Google Scholar
• Ottevanger PB. Ovarian cancer stem cells more questions than answers. Semin Cancer Biol. 2017;44:67–71. doi:10.1016/j.semcancer.2017.04.009
   PubMed Web of Science ®Google Scholar
• Moufarrij S, Dandapani M, Arthofer E, et al. Epigenetic therapy for ovarian cancer: promise and progress. Clin Epigenetics. 2019;11(1):7. doi:10.1186/s13148-018-0602-0
   PubMed Web of Science ®Google Scholar
• Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284–296. doi:10.3322/caac.21456
   PubMed Web of Science ®Google Scholar
• Yang C, Xia BR, Zhang ZC, Zhang YJ, Lou G, Jin WL. Immunotherapy for ovarian cancer: adjuvant, combination, and neoadjuvant. Front Immunol. 2020;11:577869. doi:10.3389/fimmu.2020.577869
   PubMed Web of Science ®Google Scholar
• Vallius T, Hynninen J, Kemppainen J, et al. (18)F-FDG-PET/CTbased total metabolic tumor volume change during neoadjuvant chemotherapy predicts outcome in advanced epithelial ovarian cancer. Eur J Nucl Med Mol Imaging. 2018;45(7):1224–1232. doi:10.1007/s00259-018-3961-z
   PubMed Web of Science ®Google Scholar
• Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 2018;81(1):17–38. doi:10.1007/s00280-017-3501-8
   PubMed Web of Science ®Google Scholar
• Davis A, Tinker AV, Friedlander M. “Platinum resistant” ovarian cancer: what is it, who to treat and how to measure benefit? Gynecol Oncol. 2014;133(3):624–631. doi:10.1016/j.ygyno.2014.02.038
   PubMed Web of Science ®Google Scholar
• He C, Lu K, Liu D, Lin W. Nanoscale metal-organic frameworks for the co-delivery of cisplatin and pooled siRNAs to enhance therapeutic efficacy in drug-resistant ovarian cancer cells. J Am Chem Soc. 2014;136(14):5181–5184. doi:10.1021/ja4098862
   PubMed Web of Science ®Google Scholar
• Yan T, Li D, Li J, et al. Effective co-delivery of doxorubicin and curcumin using a glycyrrhetinic acid-modified chitosan-cystamine-poly(epsilon-caprolactone) copolymer micelle for combination cancer chemotherapy. Colloids Surf B Biointerfaces. 2016;145:526–538. doi:10.1016/j.colsurfb.2016.05.070
   PubMed Web of Science ®Google Scholar
• Zhang F, Li M, Wang J, Liang X, Su Y, Wang W. Finding new tricks for old drugs: tumoricidal activity of non-traditional antitumor drugs. AAPS PharmSciTech. 2016;17(3):539–552. doi:10.1208/s12249-016-0518-y
   PubMed Web of Science ®Google Scholar
• Huang P, Wang G, Wang Z, et al. Floxuridine-chlorambucil conjugate nanodrugs for ovarian cancer combination chemotherapy. Colloids Surf B Biointerfaces. 2020;194:111164. doi:10.1016/j.colsurfb.2020.111164
   PubMed Web of Science ®Google Scholar
• Dong L, Zhang X, Cai L, et al. Targeted MRI and chemotherapy of ovarian cancer with clinic available nano-drug based nanoprobe. Biomed Pharmacother. 2020;130:110585. doi:10.1016/j.biopha.2020.110585
   PubMed Web of Science ®Google Scholar
• Raja FA, Chopra N, Ledermann JA. Optimal first-line treatment in ovarian cancer. Ann Oncol. 2012;23(Suppl 10):x118–27. doi:10.1093/annonc/mds315
   PubMed Web of Science ®Google Scholar
• Zhang X, Liu Y, Kim YJ, Mac J, Zhuang R, Wang P. Co-delivery of carboplatin and paclitaxel via cross-linked multilamellar liposomes for ovarian cancer treatment. RSC Adv. 2017;7(32):19685–19693. doi:10.1039/c7ra01100h
   PubMed Web of Science ®Google Scholar
• Thibault B, Genre L, Le Naour A, et al. DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death. Sci Rep. 2018;8(1):17862. doi:10.1038/s41598-018-35860-z
   PubMed Web of Science ®Google Scholar
• Wanderley CW, Colón DF, Luiz JPM, et al. Paclitaxel reduces tumor growth by reprogramming tumor-associated macrophages to an M1 profile in a TLR4-dependent manner. Cancer Res. 2018;78(20):5891–5900. doi:10.1158/0008-5472.CAN-17-3480
   PubMed Web of Science ®Google Scholar
• Tourell MC, Shokoohmand A, Landgraf M, et al. The distribution of the apparent diffusion coefficient as an indicator of the response to chemotherapeutics in ovarian tumour xenografts. Sci Rep. 2017;7(1):42905. doi:10.1038/srep42905
   PubMed Web of Science ®Google Scholar
• Satpathy M, Wang L, Zielinski RJ, et al. Targeted drug delivery and image-guided therapy of heterogeneous ovarian cancer using HER2-targeted theranostic nanoparticles. Theranostics. 2019;9(3):778–795. doi:10.7150/thno.29964
   PubMed Web of Science ®Google Scholar
• Boyd LR, Muggia FM. Carboplatin/Paclitaxel induction in ovarian cancer: the finer points. Oncology. 2018;32(8):418–20, 422–4.
   PubMed Web of Science ®Google Scholar
• Bisch SP, Sugimoto A, Prefontaine M, et al. Treatment tolerance and side effects of intraperitoneal carboplatin and dose-dense intravenous paclitaxel in ovarian cancer. J Obstet Gynaecol Can. 2018;40(10):1283–1287 e1. doi:10.1016/j.jogc.2018.01.028
   PubMed Web of Science ®Google Scholar
• Huang M, Liang C, Tan C, et al. Liposome co-encapsulation as a strategy for the delivery of curcumin and resveratrol. Food Funct. 2019;10(10):6447–6458. doi:10.1039/c9fo01338e
   PubMed Web of Science ®Google Scholar
• Lu L, Zhao X, Fu T, et al. An iRGD-conjugated prodrug micelle with blood-brain-barrier penetrability for anti-glioma therapy. Biomaterials. 2020;230:119666. doi:10.1016/j.biomaterials.2019.119666
   PubMed Web of Science ®Google Scholar
• Zhu Y, Liu C, Pang Z. Dendrimer-based drug delivery systems for brain targeting. Biomolecules. 2019;9(12):790. doi:10.3390/biom9120790
   PubMed Web of Science ®Google Scholar
• Li H, Somiya M, Tatematsu K, Kuroda S. Construction of a macrophage-targeting bio-nanocapsule-based nanocarrier. Methods Mol Biol. 2020;2059:299–313. doi:10.1007/978-1-4939-9798-5_16
   PubMedGoogle Scholar
• Wan H, Cao Y, Lo LW, Zhao J, Sepúlveda N, Wang C. Flexible carbon nanotube synaptic transistor for neurological electronic skin applications. ACS Nano. 2020;14(8):10402–10412. doi:10.1021/acsnano.0c04259
   PubMed Web of Science ®Google Scholar
• Rhodes KR, Green JJ. Nanoscale artificial antigen presenting cells for cancer immunotherapy. Mol Immunol. 2018;98:13–18. doi:10.1016/j.molimm.2018.02.016
   PubMed Web of Science ®Google Scholar
• Laine AL, Gravier J, Henry M, et al. Conventional versus stealth lipid nanoparticles: formulation and in vivo fate prediction through FRET monitoring. J Control Release. 2014;188:1–8. doi:10.1016/j.jconrel.2014.05.042
   PubMed Web of Science ®Google Scholar
• de Sousa Cunha F, Dos Santos Pereira LN, de Costa ESTP, de Sousa Luz RA, Nogueira Mendes A. Development of nanoparticulate systems with action in breast and ovarian cancer: nanotheragnostics. J Drug Target. 2019;27(7):732–741. doi:10.1080/1061186X.2018.1523418
   PubMed Web of Science ®Google Scholar
• Sivasankarapillai VS, Das SS, Sabir F, et al. Progress in natural polymer engineered biomaterials for transdermal drug delivery systems. Mater Today Chem. 2021;19:100382. doi:10.1016/j.mtchem.2020.100382
   Web of Science ®Google Scholar
• Mohammadzadeh V, Barani M, Amiri MS, et al. Applications of plant-based nanoparticles in nanomedicine: a review. Sustain Chem Pharm. 2022;25:100606. doi:10.1016/j.scp.2022.100606
   Web of Science ®Google Scholar
• Er S, Laraib U, Arshad R, et al. Amino acids, peptides, and proteins: implications for nanotechnological applications in biosensing and drug/gene delivery. Nanomaterials. 2021;(11):11. doi:10.3390/nano11113002
   Web of Science ®Google Scholar
• Arshad R, Fatima I, Sargazi S, et al. Novel perspectives towards RNA-based nano-theranostic approaches for cancer management. Nanomaterials. 2021;11(12):3330. doi:10.3390/nano11123330
   Web of Science ®Google Scholar
• Barani M, Bilal M, Sabir F, Rahdar A, Kyzas GZ. Nanotechnology in ovarian cancer: diagnosis and treatment. Life Sci. 2021;266:118914. doi:10.1016/j.lfs.2020.118914
   PubMed Web of Science ®Google Scholar
• Luo X, Li B, Zhang X, et al. Dual-functional lipid-like nanoparticles for delivery of mRNA and MRI contrast agents. Nanoscale. 2017;9(4):1575–1579. doi:10.1039/c6nr08496f
   PubMed Web of Science ®Google Scholar
• Song J, Zhang N, Zhang L, et al. IR780-loaded folate-targeted nanoparticles for near-infrared fluorescence image-guided surgery and photothermal therapy in ovarian cancer. Int J Nanomedicine. 2019;14:2757–2772. doi:10.2147/IJN.S203108
   PubMed Web of Science ®Google Scholar
• Huo M, Wang H, Zhang Y, et al. Co-delivery of silybin and paclitaxel by dextran-based nanoparticles for effective anti-tumor treatment through chemotherapy sensitization and microenvironment modulation. J Control Release. 2020;321:198–210. doi:10.1016/j.jconrel.2020.02.017
   PubMed Web of Science ®Google Scholar
• Cai L, Xu G, Shi C, Guo D, Wang X, Luo J. Telodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin: a synergistic combination nanotherapy for ovarian cancer treatment. Biomaterials. 2015;37:456–468. doi:10.1016/j.biomaterials.2014.10.044
   PubMed Web of Science ®Google Scholar
• Khan MM, Madni A, Tahir N, et al. Co-delivery of curcumin and cisplatin to enhance cytotoxicity of cisplatin using lipid-chitosan hybrid nanoparticles. Int J Nanomedicine. 2020;15:2207–2217. doi:10.2147/IJN.S247893
   PubMed Web of Science ®Google Scholar
• Zhang Z, Ma L, Luo J. Chondroitin sulfate-modified liposomes for targeted co-delivery of doxorubicin and retinoic acid to suppress breast cancer lung metastasis. Pharmaceutics. 2021;13(3):Mar. doi:10.3390/pharmaceutics13030406
   Web of Science ®Google Scholar
• Zahednezhad F, Saadat M, Valizadeh H, Zakeri-Milani P, Baradaran B. Liposome and immune system interplay: challenges and potentials. J Control Release. 2019;305:194–209. doi:10.1016/j.jconrel.2019.05.030
   PubMed Web of Science ®Google Scholar
• Mohamed M, Abu Lila AS, Shimizu T, et al. PEGylated liposomes: immunological responses. Sci Technol Adv Mater. 2019;20(1):710–724. doi:10.1080/14686996.2019.1627174
   PubMed Web of Science ®Google Scholar
• Abu Lila AS, Ishida T. Liposomal delivery systems: design optimization and current applications. Biol Pharm Bull. 2017;40(1):1–10. doi:10.1248/bpb.b16-00624
   PubMed Web of Science ®Google Scholar
• Roh YG, Shin SW, Kim SY, et al. Protein nanoparticle fabrication for optimized reticuloendothelial system evasion and tumor accumulation. Langmuir. 2019;35(11):3992–3998. doi:10.1021/acs.langmuir.8b03776
   PubMed Web of Science ®Google Scholar
• Chen Z, Moon JJ, Cheng W. Quantitation and stability of protein conjugation on liposomes for controlled density of surface epitopes. Bioconjug Chem. 2018;29(4):1251–1260. doi:10.1021/acs.bioconjchem.8b00033
   PubMed Web of Science ®Google Scholar
• Eroğlu İ, Ibrahim M. Liposome-ligand conjugates: a review on the current state of art. J Drug Target. 2020;28(3):225–244. doi:10.1080/1061186X.2019.1648479
   PubMed Web of Science ®Google Scholar
• Kou L, Sun R, Jiang X, et al. Tumor microenvironment-responsive, multistaged liposome induces apoptosis and ferroptosis by amplifying oxidative stress for enhanced cancer therapy. ACS Appl Mater Interfaces. 2020;12(27):30031–30043. doi:10.1021/acsami.0c03564
   PubMed Web of Science ®Google Scholar
• Wang D, Chen W, Li H, et al. Folate-receptor mediated pH/reduction-responsive biomimetic nanoparticles for dually activated multi-stage anticancer drug delivery. Int J Pharm. 2020;585:119456. doi:10.1016/j.ijpharm.2020.119456
   PubMed Web of Science ®Google Scholar
• Wehbe Z, Nasser SA, El-Yazbi A, Nasreddine S, Eid AH. Estrogen and bisphenol A in hypertension. Curr Hypertens Rep. 2020;22(3):23. doi:10.1007/s11906-020-1022-z
   PubMed Web of Science ®Google Scholar
• Bogush TA, Basharina AA, Bogush EA, Ryabinina OM, Tjulandina AS, Tjulandin SA. Estrogen receptors alpha and beta in ovarian cancer: expression level and prognosis. Dokl Biochem Biophys. 2018;482(1):249–251. doi:10.1134/S1607672918050058
   PubMed Web of Science ®Google Scholar
• Ajani MA, Salami A, Awolude OA, Oluwasola AO. Hormone-receptor expression status of epithelial ovarian cancer in Ibadan, South-western Nigeria. Pan Afr Med J. 2017;27:259. doi:10.11604/pamj.2017.27.259.11883
   PubMedGoogle Scholar
• Raveendran R, Chen F, Kent B, Stenzel MH. Estrone-decorated polyion complex micelles for targeted melittin delivery to hormone-responsive breast cancer cells. Biomacromolecules. 2020;21(3):1222–1233. doi:10.1021/acs.biomac.9b01681
   PubMed Web of Science ®Google Scholar
• Hao Q, Xu G, Yang Y, et al. Oestrone-targeted liposomes for mitoxantrone delivery via oestrogen receptor - synthesis, physicochemical characterization and in-vitro evaluation. J Pharm Pharmacol. 2017;69(8):991–1001. doi:10.1111/jphp.12736
   PubMed Web of Science ®Google Scholar
• Patel O, Muller CJF, Joubert E, et al. Pharmacokinetic interaction of green rooibos extract with atorvastatin and metformin in rats. Front Pharmacol. 2019;10:1243. doi:10.3389/fphar.2019.01243
   PubMed Web of Science ®Google Scholar
• Yang Y, Lu X, Liu Q, et al. Palmitoyl ascorbate and doxorubicin co-encapsulated liposome for synergistic anticancer therapy. Eur J Pharm Sci. 2017;105:219–229. doi:10.1016/j.ejps.2017.05.038
   PubMed Web of Science ®Google Scholar
• Chen T, Gong T, Zhao T, Fu Y, Zhang Z, Gong T. A comparison study between lycobetaine-loaded nanoemulsion and liposome using nRGD as therapeutic adjuvant for lung cancer therapy. Eur J Pharm Sci. 2018;111:293–302. doi:10.1016/j.ejps.2017.09.041
   PubMed Web of Science ®Google Scholar
• Penaloza JP, Marquez-Miranda V, Cabana-Brunod M, et al. Intracellular trafficking and cellular uptake mechanism of PHBV nanoparticles for targeted delivery in epithelial cell lines. J Nanobiotechnology. 2017;15(1). doi:10.1186/s12951-016-0241-6
   PubMed Web of Science ®Google Scholar
• Tunsirikongkon A, Pyo YC, Kim DH, Lee SE, Park JS. Optimization of polyarginine-conjugated PEG lipid grafted proliposome formulation for enhanced cellular association of a protein drug. Pharmaceutics. 2019;11(6):Jun. doi:10.3390/pharmaceutics11060272
   Web of Science ®Google Scholar
• Nunes SS, Fernandes RS, Cavalcante CH, et al. Influence of PEG coating on the biodistribution and tumor accumulation of pH-sensitive liposomes. Drug Deliv Transl Res. 2019;9(1):123–130. doi:10.1007/s13346-018-0583-8
   PubMed Web of Science ®Google Scholar
• Franco MS, Roque MC, de Barros ALB, de Oliveira Silva J, Cassali GD, Oliveira MC. Investigation of the antitumor activity and toxicity of long-circulating and fusogenic liposomes co-encapsulating paclitaxel and doxorubicin in a murine breast cancer animal model. Biomed Pharmacother. 2019;109:1728–1739. doi:10.1016/j.biopha.2018.11.011
   PubMed Web of Science ®Google Scholar
• Caban-Toktas S, Sahin A, Lule S, et al. Combination of Paclitaxel and R-flurbiprofen loaded PLGA nanoparticles suppresses glioblastoma growth on systemic administration. Int J Pharm. 2020;578:119076. doi:10.1016/j.ijpharm.2020.119076
   PubMed Web of Science ®Google Scholar
• Liu Y, Qiao Z, Gao J, et al. Hydroxyapatite-bovine serum albumin-paclitaxel nanoparticles for locoregional treatment of osteosarcoma. Adv Healthc Mater. 2021;10(2):e2000573. doi:10.1002/adhm.202000573
   PubMed Web of Science ®Google Scholar
• Yan C, Liang N, Li Q, Yan P, Sun S. Biotin and arginine modified hydroxypropyl-beta-cyclodextrin nanoparticles as novel drug delivery systems for paclitaxel. Carbohydr Polym. 2019;216:129–139. doi:10.1016/j.carbpol.2019.04.024
   PubMed Web of Science ®Google Scholar
• Thakur S, Singh H, Singh A, et al. Thermosensitive injectable hydrogel containing carboplatin loaded nanoparticles: a dual approach for sustained and localized delivery with improved safety and therapeutic efficacy. J Drug Deliv Sci Technol. 2020;58:101817. doi:10.1016/j.jddst.2020.101817
   Web of Science ®Google Scholar
• Alex AT, Joseph A, Shavi G, Rao JV, Udupa N. Development and evaluation of carboplatin-loaded PCL nanoparticles for intranasal delivery. Drug Deliv. 2016;23(7):2144–2153. doi:10.3109/10717544.2014.948643
   PubMed Web of Science ®Google Scholar
• Zhu X, Peng Y, Qiu L. Amino-functionalized nano-vesicles for enhanced anticancer efficacy and reduced myelotoxicity of carboplatin. Colloids Surf B Biointerfaces. 2017;157:56–64. doi:10.1016/j.colsurfb.2017.05.041
   PubMed Web of Science ®Google Scholar
• Fu Y, Ding Y, Zhang L, Zhang Y, Liu J, Yu P. Poly ethylene glycol (PEG)-Related controllable and sustainable antidiabetic drug delivery systems. Eur J Med Chem. 2021;217:113372. doi:10.1016/j.ejmech.2021.113372
   PubMed Web of Science ®Google Scholar
• Chen EM, Quijano AR, Seo YE, et al. Biodegradable PEG-poly(omega-pentadecalactone-co-p-dioxanone) nanoparticles for enhanced and sustained drug delivery to treat brain tumors. Biomaterials. 2018;178:193–203. doi:10.1016/j.biomaterials.2018.06.024
   PubMed Web of Science ®Google Scholar
• Haggag Y, Abdel-Wahab Y, Ojo O, et al. Preparation and in vivo evaluation of insulin-loaded biodegradable nanoparticles prepared from diblock copolymers of PLGA and PEG. Int J Pharm. 2016;499(1–2):236–246. doi:10.1016/j.ijpharm.2015.12.063
   PubMed Web of Science ®Google Scholar
• Mo L, Song JG, Lee H, et al. PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure. Nanomedicine. 2018;14(2):557–567. doi:10.1016/j.nano.2017.12.003
   PubMed Web of Science ®Google Scholar
• Novohradsky V, Zajac J, Vrana O, Kasparkova J, Brabec V. Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells. Oncotarget. 2018;9(47):28456–28473. doi:10.18632/oncotarget.25466
   PubMedGoogle Scholar
• Antunes IF, Hospers GAP, Sijbesma JWA, et al. Monitoring the crosstalk between the estrogen receptor and human epidermal growth factor receptor 2 with PET. Mol Imaging Biol. 2020;22(5):1218–1225. doi:10.1007/s11307-020-01496-7
   PubMed Web of Science ®Google Scholar
• Choi JH, Lee JS, Park KM, Bae JW, Lee Y, Park KD. Multi-layered nanogels with MMP-sheddable PEG masks: preparation and promotion of tumor cell uptake by controlling surface characteristics. Colloids Surf B Biointerfaces. 2017;156:71–78. doi:10.1016/j.colsurfb.2017.05.007
   PubMed Web of Science ®Google Scholar
• Yazdi JR, Tafaghodi M, Sadri K, et al. Folate targeted PEGylated liposomes for the oral delivery of insulin: in vitro and in vivo studies. Colloids Surf B Biointerfaces. 2020;194:111203. doi:10.1016/j.colsurfb.2020.111203
   PubMed Web of Science ®Google Scholar
• Doucette MM, Stevens VL. Folate receptor function is regulated in response to different cellular growth rates in cultured mammalian cells. J Nutr. 2001;131(11):2819–2825. doi:10.1093/jn/131.11.2819
   PubMed Web of Science ®Google Scholar
• Wang X, Wang Q, Liu Z, Zheng X. Preparation, pharmacokinetics and tumour-suppressive activity of berberine liposomes. J Pharm Pharmacol. 2017;69(6):625–632. doi:10.1111/jphp.12692
   PubMed Web of Science ®Google Scholar
• Du Y, Wang Z, Wang T, et al. Improved antitumor activity of novel redox-responsive paclitaxel-encapsulated liposomes based on disulfide phosphatidylcholine. Mol Pharm. 2020;17(1):262–273. doi:10.1021/acs.molpharmaceut.9b00988
   PubMed Web of Science ®Google Scholar
• Cabrera M, Lecot N, Fernandez M, Gambini JP, Porcal W, Cabral P. (99m)Tc Stearyl 6-(benzylidenehydrazinyl) nicotinamide liposomes as tumor permeability evaluation tracer. AAPS PharmSciTech. 2021;22(3):115. doi:10.1208/s12249-021-01984-1
   PubMed Web of Science ®Google Scholar